Kaituo Pharmaceutical-B (09939.HK) announced that its self-developed and potentially pioneering clinical trial of 1.0% KX-826 tincture to treat androgenic alopecia in adult Chinese men has recently been approved by the State Drug Administration to evaluate the efficacy and safety of 1.0% KX-826 tincture for topical treatment of adult male AGA patients in China. The company's pre-clinical research showed that compared to the 0.5% dosage form of KX-826 tincture used in the previous phase III clinical trial, the 1.0% dosage form of this tincture significantly increased the residual concentration on human scalp cells, which is expected to improve clinical efficacy.
开拓药业-B(09939.HK)：KX-826酊1.0%治疗中国成年男性雄激素性脱发的临床试验获NMPA批准
Kaituo Pharmaceutical-B (09939.HK): KX-826 tincture 1.0% clinical trial for androgenic alopecia in adult Chinese men approved by NMPA
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.